Tratamiento quirúrgico de rescate en paciente con melanoma metastásico con mutación BRAF V600E

Miguel, Maite de; Jimeno, Jaime; Vidal, Joana; Segura, Sonia; Lorente, Leyre.
Cir. Esp. (Ed. impr.) ; 96(10): 665-666, dic. 2018. ilus
Artículo en Español | IBECS (España) | ID: ibc-176541

Documentos relacionados

  1. Melanoma: Advances in Targeted Therapy and Molecular Markers.
  2. Sirt5 is dispensable for Braf<sup>V600E</sup> -mediated cutaneous melanoma development and growth in vivo.
  3. Relapse of melanoma presenting as jejunal intussusception.
  4. Development of a potent small-molecule degrader against oncogenic BRAF<sup>V600E</sup> protein that evades paradoxical MAPK activation.
  5. Modelling bistable tumour population dynamics to design effective treatment strategies.
  6. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
  7. Considering adjuvant therapy for stage II melanoma.
  8. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
  9. Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
  10. Enteroenteric intussusception caused by a small bowel metastatic cutaneous melanoma.